Literature DB >> 9641381

The Borås experience of endoscopic thoracic sympathicotomy for palmar, axillary, facial hyperhidrosis and facial blushing.

L O Rex1, C Drott, G Claes, G Göthberg, P Dalman.   

Abstract

OBJECTIVE: To study the outcome of endoscopic thoracic sympaticotomy (ETS) for palmar, axillary, facial hyperhidrosis and facial blushing.
SUBJECTS: 1152 patients, 59% women and 41% men. INTERVENTION: ETS was performed by transection of the sympathetic chain where it overlies the second and third rib. The nerve was divided also over the fourth rib in patients with axillary hyperhidrosis. Questionnaires were sent to all patients. MAIN OUTCOME MEASURES: The effect of surgery was assessed by a 10 grad visual analogue scale (VAS) by the patients. The results were divided into effect rate (the effect on the symptom) and overall satisfaction rate, taking into account any side effects and complications apart from the effect.
RESULTS: The response rate was 90%. The mean follow up time, effect rate and overall satisfaction rate were: 38 months for palmar hyperhidrosis, 99.4% and 87%; 26 months for axillary hyperhidrosis, 94.5% and 68%; 31 months for facial hyperhidrosis, 97% and 76%; 8 months for facial blushing, 96% and 85%.
CONCLUSION: ETS is a very effective procedure in palmar, axillary and facial hyperhidrosis and facial blushing. The overall satisfaction rate is very good for palmar hyperhidrosis and facial blushing, not equally good but acceptable for facial hyperhidrosis. The lower satisfaction rate in patients with axillary hyperhidrosis makes this a questionable indication for ETS.

Entities:  

Mesh:

Year:  1998        PMID: 9641381     DOI: 10.1080/11024159850191094

Source DB:  PubMed          Journal:  Eur J Surg Suppl        ISSN: 1102-416X


  22 in total

1.  Treating hyperhidrosis. Surgery and botulinum toxin are treatments of choice in severe cases.

Authors:  J Collin; P Whatling
Journal:  BMJ       Date:  2000-05-06

Review 2.  Thoracoscopic sympathectomy for palmar hyperhidrosis. Ablate or resect?

Authors:  M Hashmonai; A Assalia; D Kopelman
Journal:  Surg Endosc       Date:  2001-04-03       Impact factor: 4.584

3.  The outcome of ganglion clipping in hyperhidrosis and blushing.

Authors:  Shah-Hwa Chou; Eing-Long Kao; Chien-Chih Lin; Meei-Feng Huang
Journal:  Clin Auton Res       Date:  2006-05-12       Impact factor: 4.435

4.  The importance of classification in sympathetic surgery and a proposed mechanism for compensatory hyperhidrosis: experience with 464 cases.

Authors:  Rafael Reisfeld
Journal:  Surg Endosc       Date:  2007-05-19       Impact factor: 4.584

5.  [Treatment of palmar and axillary hyperhidrosis: thoracoscopic resection of the sympathetic chain].

Authors:  R Rieger; S Pedevilla; S Pöchlauer
Journal:  Chirurg       Date:  2008-12       Impact factor: 0.955

Review 6.  Thoracic sympathectomy: a review of current indications.

Authors:  Moshe Hashmonai; Alan E P Cameron; Peter B Licht; Chris Hensman; Christoph H Schick
Journal:  Surg Endosc       Date:  2015-06-27       Impact factor: 4.584

7.  Do children tolerate thoracoscopic sympathectomy better than adults?

Authors:  Zvi Steiner; Zahavi Cohen; Oleg Kleiner; Ibrahim Matar; Jorge Mogilner
Journal:  Pediatr Surg Int       Date:  2007-11-13       Impact factor: 1.827

8.  Long-term results of a randomized controlled trial of T2 versus T2-T3 ablation in endoscopic thoracic sympathectomy for palmar hyperhidrosis.

Authors:  Wilson Ong; Alvin Lee; Wee Boon Tan; Davide Lomanto
Journal:  Surg Endosc       Date:  2015-07-07       Impact factor: 4.584

Review 9.  The correlation between the method of sympathetic ablation for palmar hyperhidrosis and the occurrence of compensatory hyperhidrosis: a review.

Authors:  Doron Kopelman; Moshe Hashmonai
Journal:  World J Surg       Date:  2008-11       Impact factor: 3.352

10.  Sustained benefit lasting one year from T4 instead of T3-T4 sympathectomy for isolated axillary hyperhidrosis.

Authors:  Marco Antonio S Munia; Nelson Wolosker; Paulo Kaufmann; José Ribas Milanes de Campos; Pedro Puech-Leão
Journal:  Clinics (Sao Paulo)       Date:  2008-12       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.